Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results